Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Lymphatic endothelium vessels considered less important. Later it was discovered that VEGF-R3 and VEGF-C/VEGF-D were the key growth factors controlling lymphatic endothelial proliferation. Markers of lymphatic endolthelium were not discovered until relatively recently. These being LYVE-1 (Jackson et al.,1999) and podoplanin (Kerjaschki,1999). Endothelium Lymphatic endothelium The lymphatic endothelium is a specialised form of epithelium, distinct from but similar to vascular endothelium. A lymph capillary endothelial cell is distinct from other endothelial cells in that collagen fibers are directly attached to its plasma membrane. Although lymphatics were first described by Hippocrates in 400BC and rediscovered as "milky veins in the gut of a